Under the Nov. 15 agreement, Celgene has agreed to sell its blockbuster psoriasis treatment, Otezla, to Amgen. Bristol-Myers Squibb is developing a competing treatment, which raised antitrust concerns about the Celgene acquisition.
Bristol-Myers Squibb has now satisfied all regulatory requirements to complete the merger, expected to close on Nov. 20. The drugmaker said it expects the Otezla divestiture to be completed promptly after the acquisition.
Read the full news release here.
More articles on pharmacy:
Drugmakers could lose $1T in sales and still be most profitable industry, analysis finds
CAR-T costs ‘not sustainable’ for hospitals, researchers say
How Walgreens, CVS see the future of pharmacy
